Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer

被引：8

作者：

Pelster, Meredith S. ^{[1
]}

Mott, Frank ^{[2
]}

Lewin, Jan ^{[3
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Canc Med, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd Unit 0432, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA

来源：

LARYNGOSCOPE | 2020年 / 130卷 / 04期

关键词：

Pembrolizumab; mucositis; laryngeal edema; HEAD; CARCINOMA; NIVOLUMAB; SAFETY;

D O I：

10.1002/lary.28038

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Pembrolizumab, an anti-PD-1 checkpoint inhibitor, is used in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who have received prior therapy with a platinum-based regimen. As a monotherapy, it is generally well tolerated, but a small percentage of patients may develop immune-mediated inflammatory reactions. We report a case of mucositis and laryngeal edema in a patient on pembrolizumab and review the literature. Laryngoscope, 130:E140-E143, 2020

引用

页码：E140 / E143

页数：4

共 15 条

[1] Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study [J].

Bauml, Joshua ;

Seiwert, Tanguy Y. ;

Pfister, David G. ;

Worden, Francis ;

Liu, Stephen V. ;

Gilbert, Jill ;

Saba, Nabil F. ;

Weiss, Jared ;

Wirth, Lori ;

Sukari, Ammar ;

Kang, Hyunseok ;

Gibson, Michael K. ;

Massarelli, Erminia ;

Powell, Steven ;

Meister, Amy ;

Shu, Xinxin ;

Cheng, Jonathan D. ;

Haddad, Robert .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14) :1542-+

[2] Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis [J].

Baxi, Shrujal ;

Yang, Annie ;

Gennarelli, Renee L. ;

Khan, Niloufer ;

Wang, Ziwei ;

Boyce, Lindsay ;

Korenstein, Deborah .

BMJ-BRITISH MEDICAL JOURNAL, 2018, 360

[3] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[4] Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab [J].

Brand, Fanny Zulay Acero ;

Suter, Nicolas ;

Adam, Jean-Philippe ;

Faulques, Bernard ;

Maietta, Antonio ;

Soulieres, Denis ;

Blais, Normand .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[5] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].

Ferris, R. L. ;

Blumenschein, G., Jr. ;

Fayette, J. ;

Guigay, J. ;

Colevas, A. D. ;

Licitra, L. ;

Harrington, K. ;

Kasper, S. ;

Vokes, E. E. ;

Even, C. ;

Worden, F. ;

Saba, N. F. ;

Iglesias Docampo, L. C. ;

Haddad, R. ;

Rordorf, T. ;

Kiyota, N. ;

Tahara, M. ;

Monga, M. ;

Lynch, M. ;

Geese, W. J. ;

Kopit, J. ;

Shaw, J. W. ;

Gillison, M. L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867

[6] Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Haanen, J. B. A. G. ;

Carbonnel, F. ;

Robert, C. ;

Kerr, K. M. ;

Peters, S. ;

Larkin, J. ;

Jordan, K. .

ANNALS OF ONCOLOGY, 2017, 28 :119-142

[7] Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial [J].

Harrington, Kevin J. ;

Ferris, Robert L. ;

Blumenschein, George, Jr. ;

Colevas, A. Dimitrios ;

Fayette, Jerome ;

Licitra, Lisa ;

Kasper, Stefan ;

Even, Caroline ;

Vokes, Everett E. ;

Worden, Francis ;

Saba, Nabil F. ;

Kiyota, Naomi ;

Haddad, Robert ;

Tahara, Makoto ;

Gruenwald, Viktor ;

Shaw, James W. ;

Monga, Manish ;

Lynch, Mark ;

Taylor, Fiona ;

DeRosa, Michael ;

Morrissey, Laura ;

Cocks, Kim ;

Gillison, Maura L. ;

Guigay, Joel .

LANCET ONCOLOGY, 2017, 18 (08) :1104-1115

[8] Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review [J].

Joshi, M. N. ;

Whitelaw, B. C. ;

Palomar, M. T. P. ;

Wu, Y. ;

Carroll, P. V. .

CLINICAL ENDOCRINOLOGY, 2016, 85 (03) :331-339

[9] Immune-related adverse events with immune checkpoint blockade: a comprehensive review [J].

Michot, J. M. ;

Bigenwald, C. ;

Champiat, S. ;

Collins, M. ;

Carbonnel, F. ;

Postel-Vinay, S. ;

Berdelou, A. ;

Varga, A. ;

Bahleda, R. ;

Hollebecque, A. ;

Massard, C. ;

Fuerea, A. ;

Ribrag, V. ;

Gazzah, A. ;

Armand, J. P. ;

Amellal, N. ;

Angevin, E. ;

Noel, N. ;

Boutros, C. ;

Mateus, C. ;

Robert, C. ;

Soria, J. C. ;

Marabelle, A. ;

Lambotte, O. .

EUROPEAN JOURNAL OF CANCER, 2016, 54 :139-148

[10] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies [J].

Naidoo, J. ;

Page, D. B. ;

Li, B. T. ;

Connell, L. C. ;

Schindler, K. ;

Lacouture, M. E. ;

Postow, M. A. ;

Wolchok, J. D. .

ANNALS OF ONCOLOGY, 2015, 26 (12) :2375-2391

← 1 2 →